Cite
HARVARD Citation
Lawitz, E. et al. (2015). A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. Journal of viral hepatitis. 22 (12), pp. 1011-1019. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Lawitz, E. et al. (2015). A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. Journal of viral hepatitis. 22 (12), pp. 1011-1019. [Online].